Article
The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 May 2014
Pelizzo M R, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D
Abstract excerpt
BACKGROUND: BRAF(V600E) mutation, which represents the most frequent genetic mutation in papillary thyroid carcinoma (PTC), is widely considered to have an adverse outcome on PTC outcome, however its real predictive value is not still well stated. The aim of the present study was to evaluate if BRAF(V600E) mutation could be useful to identify within patients with intrathyroid ultrasound-N0 PTC those who require...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.